Last updated: February 15, 2026
What is NDC 64896-0663?
NDC 64896-0663 corresponds to Shering-Plough’s (now part of Merck) branded drug Intron A (interferon alfa-2b), indicated primarily for diseases such as melanoma, certain leukemias, hepatitis B and C, and other viral infections. It is a biologic with a complex manufacturing process, classified as a specialty drug.
Market Overview
Current Market Size
The global interferon alfa-2b market, driven by hepatitis B and C treatments and certain cancers, was valued at approximately $200 million in 2022. The United States accounts for around 60% of this market, with a revenue of approximately $120 million.
Market Dynamics
- Indication Expansion: New indications or combination therapies could expand usage.
- Generic Competition: No generic versions of the branded form are available currently due to patent protections.
- Biosimilars: The expiration of patents on similar biologics could introduce biosimilar competition within the next 5–7 years, possibly reducing prices.
Regulatory Environment
- Patent Status: Original patents expired in 2019 for some formulations, but trade secrets and manufacturing rights restrict biosimilar entry.
- Pricing Policy Trends: Increasing attention on drug pricing, especially for biologics, influences affordability and reimbursement.
Price Trends and Projections
Current Pricing
- Average Wholesale Price (AWP): The current AWP for a 3-million-unit vial of Intron A is approximately $3,500.
- Per Unit Cost: Approximately $1.16 per 1,000 units.
Recent Price Movements
- Over the past five years, the price per dose has increased steadily, roughly 3–4% annually, driven by manufacturing costs and limited competition.
- No significant discounts or rebates are publicly reported, although payer negotiations can significantly lower effective prices.
Future Price Trajectory (2023–2028)
| Year |
Estimated Average Price per Vial |
Key Drivers |
| 2023 |
$3,600 |
Pricing stability, no biosimilar entry yet |
| 2024 |
$3,660 |
Continued cost inflation, emerging biosimilar threat |
| 2025 |
$3,750 |
First biosimilar entry expected, potential price decline |
| 2026 |
$3,450 |
Biosimilar competition matures, prices stabilize or decline |
| 2027 |
$3,300 |
Market saturation, cost containment measures |
| 2028 |
$3,150 |
Increased biosimilar market penetration |
Factors Impacting Price Projections
- Biosimilar Market Entry: Expected around 2024–2026, potentially reducing prices by 20–40%.
- Patent Litigation and Exclusivity: Patent litigation delays or extensions could prolong current pricing.
- Reimbursement Policies: CMS and private insurers may negotiate aggressive rebates, impacting net prices.
- Manufacturing Costs: Technology improvements could lower costs, supporting price reductions.
Competitive Landscape
| Competitors and Alternatives |
Status |
| Peginterferon alfa-2a (Pegasys) |
FDA approved, marketed by Roche for hepatitis B and C |
| Biosimilars (pending approval) |
Several biosimilar candidates entered the development pipeline; approval expected between 2024–2026 |
| Other interferons (e.g., IFN beta) |
Used for different indications; not directly competitive |
Regulatory and Policy Risks
- Potential price controls or negotiation strategies from CMS could suppress prices.
- Delay or rejection of biosimilar approvals may preserve current pricing for longer.
Key Takeaways
- Market size: Approximately $200 million globally with U.S. dominance.
- Price trend: Currently around $3,600 per vial with slight increases annually.
- Biosimilar impact: Entry anticipated within 2–3 years could lead to significant price reductions.
- Market risks: Patent litigations, policy shifts, and manufacturing costs influence future prices.
- Investment outlook: Short-term stability likely; long-term prices may decline with biosimilar competition.
FAQs
-
When will biosimilars for NDC 64896-0663 likely enter the market?
Expect approvals around 2024–2026, with initial entries in select markets.
-
How much could biosimilar entry reduce prices?
Typically 20–40%, depending on market competition, regulatory approval timing, and negotiated rebates.
-
Are there significant off-label uses that could affect market size?
Off-label use exists but remains limited without formal indications or label expansion.
-
What are the main hurdles for biosimilar market entry in this segment?
Patent protections, manufacturing complexity, and regulatory approvals.
-
How could future policy changes affect prices?
Price controls, negotiations, or new reimbursement policies could suppress prices further.
Citations
[1] Evaluate Pharma, “Interferon Market & Price Analysis,” 2022.
[2] IQVIA, “Pharmaceutical Market Data,” 2022.
[3] U.S. FDA, “Biosimilar Approval Pipeline,” 2023.
[4] CMS, “Drug Pricing and Reimbursement Policies,” 2022.
